Clinical Trial

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-03; most recent amendment 2026-02-27.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07064122
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Haematologic Neoplasms
Enrollment 72 participants
Start Date 2025-11-03
Primary Completion 2028-10-20 (estimated)
Study Completion 2028-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-02